Talphera (TLPH) Total Non-Current Liabilities (2010 - 2026)
Talphera (TLPH) posted quarterly Total Non-Current Liabilities of $10.5 million for Q1 2026, up 23.58% year-over-year from $8.5 million in Q1 2025, and up 2.1% quarter-over-quarter from $10.3 million in Q4 2025.
Talphera (TLPH) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Talphera's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $10.5 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 23.58% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (up 23.58% YoY), while the FY2025 annual figure was $10.3 million, up 12.36% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $10.5 million, up from $10.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $25.6 million in Q1 2022, with the low at $4.5 million in Q4 2023.
- The 5-year median for Total Non-Current Liabilities is $9.7 million (2025), against an average of $11.8 million.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities slumped 81.97% in 2022, then surged 103.32% in 2024.
- Talphera's Total Non-Current Liabilities stood at $18.6 million in 2022, then tumbled by 75.71% to $4.5 million in 2023, then soared by 103.32% to $9.2 million in 2024, then advanced by 12.36% to $10.3 million in 2025, then gained by 2.1% to $10.5 million in 2026.
- Business Quant data shows TLPH's Total Non-Current Liabilities at $10.5 million in Q1 2026, $10.3 million in Q4 2025, and $9.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Talphera | 90.35 Mn | 90.35 Mn | - | 10.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.69 Mn |
| Mar 31, 2026 | 10.52 Mn |
| Dec 31, 2025 | 10.31 Mn |
| Sep 30, 2025 | 9.71 Mn |
| Jun 30, 2025 | 9.13 Mn |
| Mar 31, 2025 | 8.52 Mn |
| Dec 31, 2024 | 9.17 Mn |
| Sep 30, 2024 | 9.29 Mn |
| Jun 30, 2024 | 9.80 Mn |
| Mar 31, 2024 | 9.66 Mn |
| Dec 31, 2023 | 4.51 Mn |
| Sep 30, 2023 | 4.95 Mn |
| Jun 30, 2023 | 7.31 Mn |
| Mar 31, 2023 | 10.26 Mn |
| Dec 31, 2022 | 18.58 Mn |
| Sep 30, 2022 | 20.77 Mn |
| Jun 30, 2022 | 22.99 Mn |
| Mar 31, 2022 | 25.63 Mn |
| Dec 31, 2021 | 28.50 Mn |
| Sep 30, 2021 | 115.18 Mn |